Biotechnology · NASDAQ
当前价格
$91.19
内在价值
使用下方计算器估算
对 BioNTech SE 运行完整的 DCF 分析，自动填充基本面数据，可调节假设参数，含敏感性热力图。
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
ROIC (TTM)
-6.6%
ROE (TTM)
-6.0%
FCF Yield
-1.17%
基于过去 12 个月的数据，BNTX 每股自由现金流为 N/A，投入资本回报率（ROIC）为 -6.6%，这些是使用 DCF 方法进行股票估值的关键输入。P/FCF 比率为 N/A，FCF 收益率为 -1.17%，是评估 BNTX 相对估值的重要参考指标。
BNTX 的内在价值取决于对未来增长率、折现率（WACC）和终值的假设。使用 MiniValuator 免费 DCF 计算器，输入你自己的假设进行估算，并查看敏感性分析热力图。
BNTX 是否被低估取决于你的 DCF 假设。如果计算出的内在价值显著高于当前市价，则可能被低估。安全边际指示低估程度。在 MiniValuator 上运行完整估值来了解。
你可以使用 MiniValuator 的 DCF 计算器对 BNTX 估值：输入代码，查看自动填充的基本面数据，调整增长率和折现率假设，即可获得含敏感性热力图的即时内在价值。
DCF（折现现金流）估值通过将公司未来预期自由现金流折现回现值来估算内在价值。对于 BNTX，你输入预期增长率和折现率（WACC），模型会根据其未来现金产生能力计算股票当前应有的价值。
WACC（加权平均资本成本）是 BNTX 估值中使用的折现率。较高的 WACC 会降低内在价值估算，较低的 WACC 则会提高。使用 MiniValuator 的敏感性热力图查看不同 WACC 假设对 BNTX DCF 估值结果的影响。
